<SEC-DOCUMENT>0001654954-24-011106.txt : 20240827
<SEC-HEADER>0001654954-24-011106.hdr.sgml : 20240827
<ACCEPTANCE-DATETIME>20240826202043
ACCESSION NUMBER:		0001654954-24-011106
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240827
DATE AS OF CHANGE:		20240826

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Quantum Biopharma Ltd.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276264
		FILM NUMBER:		241242956

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FSD Pharma Inc.
		DATE OF NAME CHANGE:	20190327
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>fsd_424b5.htm
<DESCRIPTION>FORM 424B5
<TEXT>
<html><head><title>fsd_424b5.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Amendment No. 1 dated August 26, 2024 </strong></p></td> <td style="width:50%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Filed pursuant to Rule 424(b)(5)</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>to Prospectus Supplement dated February 16, 2024</strong></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Registration No. 333-276264</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(To Prospectus dated January 4, 2024) </p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>QUANTUM BIOPHARMA LTD.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(formerly known as FSD Pharma Inc.)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to $2,235,601 Class B Subordinate Voting Shares</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This Amendment No. 1 (&#8220;Amendment&#8221;) amends certain information contained in our prospectus supplement, dated February 16, 2024 (the &#8220;ATM Prospectus Supplement&#8221;), and the accompanying prospectus, dated January 4, 2024 (the &#8220;Base Prospectus,&#8221; and together with the ATM Prospectus Supplement, any supplement thereto, and the documents deemed incorporated by reference in each, collectively, the &#8220;Prospectus&#8221;), which relate to the offer and sale of our Class B Subordinate Voting Shares (&#8220;Class B Shares&#8221;) of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc. (&#8220;we&#8221; &#8220;us&#8221; or the &#8220;Company&#8221;) in an &#8220;at-the-market&#8221; offering &nbsp;pursuant to a Sales Agreement dated February 16, 2024 with H.C. Wainwright &amp; Co., LLC.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You should carefully read the entire Prospectus and this Amendment before investing in our Class B Shares. This Amendment should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Amendment is not complete without, and may only be delivered or utilized in connection with the Prospectus and any future amendments or supplements thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This Amendment is being filed to reflect that on August 15, 2024, the Company completed a share consolidation of its issued and outstanding class A multiple voting shares (&#8220;<strong>Class A Shares</strong>&#8221;) and <strong>Class B Shares</strong> on the basis of one (1) post-consolidation Class A Share and Class B Share for every sixty-five (65) pre-consolidation Class A Shares and Class B Shares (the &#8220;<strong>Consolidation</strong>&#8221;).&nbsp; The Consolidation was part of the Company&#8217;s plan to regain compliance with the minimum bid price requirements on The Nasdaq Stock Market (&#8220;Nasdaq&#8221;).&nbsp; No assurance can be made that the Company will regain compliance with the minimum bid price requirements on Nasdaq and that its Class B Shares will remain eligible for listing on Nasdaq.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After the Consolidation on August 15, 2024, the issued and outstanding Class B Subordinate Voting Shares were reduced from 84,531,149 Class B Shares to 1,300,727 Class B Shares and the Class A Shares were reduced from 72 Class A Shares to 6 Class A Shares, which included 4 Class A Shares issued in a non-brokered private placement which closed on the same day of the Consolidation. &nbsp;The exercise price or conversion price and the number of Class B Shares issuable under any of the Company&#8217;s outstanding convertible securities was proportionately adjusted upon the Consolidation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective as of August 15, 2024, the Company changed its name from FSD Pharma Inc. to Quantum Biopharma Ltd. and its ticker symbol on Nasdaq and the Canadian Securities Exchange from &#8220;HUGE to &#8220;QNTM.&#8221;&nbsp; On August 23, 2024, the last report sales price of our Class B Shares under the symbol &#8220;QNTM&#8221; on Nasdaq was $4.21 per share. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From February 16, 2024, through the date of this Amendment, we have sold under the Sales Agreement an aggregate of 817,789 Class B Shares on a post-consolidation basis, pursuant to the Sales Agreement, for gross proceeds of approximately $8,918,631 leaving approximately $2,235,601 available to be offered by this Amendment, the ATM Prospectus Supplement and the accompanying Base Prospectus. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Investing in our Class B Shares involves a very high degree of risk. Please review carefully the information under the heading&nbsp;</strong>&#8220;<strong>Risk Factors</strong>&#8221;<strong>&nbsp;beginning on page S-12 of the ATM Prospectus Supplement and similar headings under the Base Prospectus, as well as documents incorporated by reference into this Amendment, the ATM Prospectus Supplement and the Base Prospectus, as well as the risks and uncertainties described in other documents we file with the Securities and Exchange Commission (&#8220;SEC&#8221;). &nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this Amendment, the ATM Prospectus and the Base Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>H.C. Wainwright &amp; Co.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The date of this Amendment No. 1 to the ATM Prospectus Supplement is August 26, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
